Literature DB >> 16839258

Thyroid disorders in chronic hepatitis C virus infection.

Alessandro Antonelli1, Clodoveo Ferri, Poupak Fallahi, Silvia Martina Ferrari, Alessandra Ghinoi, Mario Rotondi, Ele Ferrannini.   

Abstract

The prevalence of thyroid disorders has been evaluated in patients with hepatitis C virus (HCV) infection by many studies. From a review of the published controlled studies, it is possible to observe that: (1) most investigated patients with chronic HCV hepatitis, while a minority evaluated hepatitis C virus antibody (HCVAb)- seropositive patients (the two conditions are not comparable with regards to thyroidal repercussions, in fact, HCVAb-seropositive patients do not necessarily display changes of the immune system present in chronically infected HCV patients); and (2) some authors selected as internal control hepatitis B virus (HBV)-infected patients, while others selected apparently healthy controls or HCVAb-negative subjects. Pooling all data about HCV-positive patients (with chronic hepatitis or HCVAb positivity) and using as control the sum of healthy controls, HBV-infected patients and sera negative for HCVAb, a significant increase of the prevalence has been observed both for thyroid autoimmune disorders (odds ratio [OR] = 1.6; 95% confidence interval = [C]) 1.4-1.9) as well as for hypothyroidism (OR = 2.9; 95% CI = 2.0-4.1). The results of the epidemiologic studies showing an association between HCV infection and thyroid cancer need to be confirmed. The abovementioned evidences seem sufficient to suggest careful thyroid monitoring during the follow-up of patients with HCV infection.

Entities:  

Mesh:

Year:  2006        PMID: 16839258     DOI: 10.1089/thy.2006.16.563

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  38 in total

Review 1.  Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers.

Authors:  Christoph Langenstein; Diana Schork; Klaus Badenhoop; Eva Herrmann
Journal:  Rev Endocr Metab Disord       Date:  2016-12       Impact factor: 6.514

Review 2.  Hepatitis C and interferon induced thyroiditis.

Authors:  Yaron Tomer
Journal:  J Autoimmun       Date:  2010-05       Impact factor: 7.094

3.  Hepatitis C: thyroid dysfunction in patients with hepatitis C on IFN-alpha therapy.

Authors:  Alessandro Antonelli; Clodoveo Ferri; Poupak Fallahi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-11       Impact factor: 46.802

4.  Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature.

Authors:  Silvia Fabiani; Poupak Fallahi; Silvia Martina Ferrari; Mario Miccoli; Alessandro Antonelli
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

Review 5.  Cytokines and HCV-related autoimmune disorders.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Ilaria Ruffilli; Poupak Fallahi
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 6.  Endocrine manifestations of hepatitis C virus infection.

Authors:  Alessandro Antonelli; Clodoveo Ferri; Silvia Martina Ferrari; Michele Colaci; Domenico Sansonno; Poupak Fallahi
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-01

Review 7.  Interferon alpha treatment and thyroid dysfunction.

Authors:  Yaron Tomer; Jason T Blackard; Nagako Akeno
Journal:  Endocrinol Metab Clin North Am       Date:  2007-12       Impact factor: 4.741

Review 8.  Interferon induced thyroiditis.

Authors:  Yaron Tomer; Francesca Menconi
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-12       Impact factor: 4.690

Review 9.  Hepatitis C virus and neurological damage.

Authors:  Shilu Mathew; Muhammed Faheem; Sara M Ibrahim; Waqas Iqbal; Bisma Rauff; Kaneez Fatima; Ishtiaq Qadri
Journal:  World J Hepatol       Date:  2016-04-28

Review 10.  Autoantibodies in chronic hepatitis C: A clinical perspective.

Authors:  Janaína Luz Narciso-Schiavon; Leonardo de Lucca Schiavon
Journal:  World J Hepatol       Date:  2015-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.